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Introduction: Even with vaccines available since 2006, rotavirus continues to be a major cause of acute
gastroenteritis globally in children under 5 years old. Finland introduced the rotavirus vaccine to its
national vaccination programme in 2009. Since then hospitalizations due to gastroenteritis caused by
rotavirus (RVGE) and of all causes (AGE) have been reduced significantly in young children.
Methods: We performed a retrospective analysis of data from register databases consisting of over 200
000 children aged 0.5–2 years. Children born before rotavirus vaccines were available (2002, 2003)
and after the implementation of rotavirus vaccination programme (2014, 2015) were followed for epi-
sodes of acute infectious gastroenteritis. We calculated the incidences of hospital outpatient and inpa-
tient episodes and used individual vaccination records to estimate the overall, total, direct and indirect
vaccine effect (VE %).
Results: Among children born in 2014 and 2015, there was a 96% reduction in inpatient RVGE episodes
and a 78% reduction in episodes of inpatient AGE compared to the pre-vaccination era, comprising the
overall VE. Direct effectiveness was 96% and 53% for RVGE and AGE respectively. Herd effect i.e. indirect
protection was estimated to be 67% against inpatient RVGE and 56% against inpatient AGE. Protection
acquired by the vaccinated children when compared to pre vaccination era i.e. the total VE was 99%
for inpatient RVGE and 79% for inpatient AGE.
Conclusions: Although overall incidences for every disease type studied were reduced, rotavirus is still
circulating with seasonality and there is a slight shift of disease towards the older age groups.
Together with changes observed in the distribution of rotavirus genotypes, our results indicate that
continuous monitoring is still necessary.
 2020 The Authors. Published by Elsevier Ltd. This is an open access article under theCCBY license (http://
creativecommons.org/licenses/by/4.0/).Rotavirus gastroenteritis (RVGE) is the leading cause of diarrhea
related morbidity and mortality globally among children younger
than 5 years [1]. Severe cases of RVGE lead to dehydration, which
in infants and toddlers generally results in the need of hospitaliza-
tion. Vaccines against RVGE have been available since 2006. How-
ever, still in 2016 rotavirus was estimated to be responsible for
more than 285 000 000 cases and over 128 000 deaths in children
under 5 years globally [1].
In Finland, the rotavirus vaccine (RotaTeq) was introduced to
the national vaccination programme in 2009. By 2014, rotavirus
vaccination had reduced hospitalisations due to RVGE by nearly
93% and saved 2.2 million euros in healthcare costs [2]. This reduc-
tion corresponds to the overall effect or impact of the vaccination
programme, including both direct and indirect protection gainedas vaccinated cohorts were compared with cohorts without
vaccination.
Rotavirus is transmitted also by the older individuals in the
population, although it is mainly the disease of the very young. It
is therefore of interest to study if the vaccination among the young
cohorts is enough to cause major indirect effects seen as herd pro-
tection. The indirect effect on its own is seen when the unvacci-
nated during the vaccination programme are compared to the
cohorts prior to the programme [3]. The largest effect a vaccination
programme can produce, however, is the total effect i.e. the differ-
ence when the individuals in the population without vaccinations
are compared to the vaccinated individuals in the population with
high vaccination coverage [3].
In this study we assessed the impact of rotavirus vaccination
programme by focusing on the age group with the highest rota-
virus incidence and morbidity; children aged 0.5–2 years [4]. Inci-
dences of both rotavirus gastroenteritis (RVGE) and acute
A. Solastie et al. / Vaccine 38 (2020) 3766–3772 3767infectious gastroenteritis (AGE) of any cause were estimated
together with information on the severity of the cases i.e. whether
the patient was admitted to the hospital (inpatient) or not (outpa-
tient). We estimated the overall effect of the vaccination pro-
gramme (VE) by comparing birth cohorts before and after
vaccination programme implementation. In addition, we estimated
total, direct and indirect VE by using the national vaccination
register.1. Methods
1.1. Study setting
In this study children born in 2002, 2003, 2014 and 2015 were
followed from the age of 6 months until their 2nd birthday for epi-
sodes of acute infectious gastroenteritis. Children born in 2014 and
2015 comprised the post-vaccination cohort and children born in
2002 and 2003 the pre-vaccination era cohort. Years 2002 and
2003 were chosen since they comprise the last birth cohorts rota-
virus vaccine had no effect on as from 2006 to 2009 rotavirus vac-
cines were available at parents’ own expense. Birth years 2014 and
2015 were chosen due to 2017 being the most recent year for
which all decisive data was available electronically, as of June
2019.
1.2. Data sources
Data used in this study was obtained from the Finnish national
healthcare registers. Information on children’s inpatient and out-
patient visits due to acute gastroenteritis was obtained from the
Care Register for Health Care (Hilmo). Hilmo is a secondary health-
care register that contains nationwide data of hospital visits in Fin-
land. Therefore this study includes only visits to Finnish hospitals
and not to primary healthcare centres. We selected children born
in Finland in 2002, 2003, 2014 and 2015 and extracted their birth-
days and the dates of death, date and the type of visits and primary
diagnosis codes for these visits. By using encrypted uniqueTable 2
Incidence of rotavirus– and acute gastroenteritis in Finnish children born in
Birth year Age in months A Person-years Rotavirus ga
Inpatient
2002 6 27406 10.51 (288)
12 27406 6.28 (172)
18 27406 3.28 (90)
2003 6 27970 7.58 (212)
12 27970 5.58 (156)
18 27970 5.65 (158)
Combined 166128 6.48 (1076)
A = Cohorts were divided into three age-groups; ‘‘600 includes episodes f
23 months.
B = (Number of cases) in parentheses.
C = Incidence of episodes [per 1000 person-years] with at least one visi
D = Incidence of episodes [per 1000 person-years] with visits due to A0
Table 1
Formulas used to calculate vaccine effectiveness (VE) from incidences.
VEoverall = (1– 21A)  100 VEtotal = (1– 2B1A)  100
VEdirect = (1– 2B2A)  100 VEindirect = (1–2A1A)  100
1A = incidence in completely unvaccinated population during 2002–2005, 2 = inci-
dence after introduction of vaccine (i.e. during 2014–2017), 2A = incidence among
unvaccinated population during 2014–2017, 2B = incidence among vaccinated
population during 2014–2017.personal identity codes we extracted the dates of rotavirus vacci-
nations from the National Vaccination Register for each child.
1.3. Data categorization
From the Care Register for Health Care, visits coded with A00-
A09 (intestinal infectious diseases) in International Classification
of Diseases, 10th revision (ICD-10) were selected. Visits were
divided into two categories by primary diagnostic codes. All visits
coded ICD-10 A00-A09 were categorised as AGE. Visits with ICD-10
A08.0 (rotaviral enteritis) as a primary diagnosis comprised the
RVGE category. The AGE category included also all A08.0 coded vis-
its; hence the RVGE acts as a definite subgroup of AGE. AGE and
RVGE were each further divided depending on the type of visit
(i.e. whether the visit was inpatient or outpatient). Consequently,
the data was analysed in four distinct groups: inpatient RVGE, out-
patient RVGE, inpatient AGE and outpatient AGE.
Cases were analysed as episodes rather than single visits. All
subsequent visits within 21 days of the last visit formed a single
episode. Episodes containing multiple codes for primary diagnosis
or type of visit were categorised by the most severe and specific
coding. Thus all episodes with at least one visit due to A08.0 were
classified as RVGE and if an episode included even a single inpa-
tient visit, the whole episode was categorised as inpatient. Epi-
sodes were divided into three age groups (6–11 months, 12–
17 months and 18–23 months) with the first visit of the episode
determining the age group it was categorised in. In the post-vacci-
nation group, children were categorised as vaccinated if they had
received at least one dose of rotavirus vaccine.
1.4. Excluded groups
Approximately 18 000 children born abroad or in unknown
locations were excluded from the study, primarily because we
were not able to assess their vaccination status. 207 children
who lacked information of birth date and personal identity code
were excluded because they could not be connected to vaccination
information or categorised into age groups. 237 children who died
within their follow up period (at less than 730 days of age) were
also excluded.
1.5. Statistical analysis
Data was acquired from the registers through Stata, and all sta-
tistical analyses were performed with R-studio (under R version
3.5.1). Person-time was calculated from the sizes of birth cohorts
with exclusions mentioned earlier. Incidences for inpatient and
outpatient RVGE and AGE were calculated by dividing the number
of episodes by person-years (pyrs). Pyrs were calculated separately2002 and 2003.
stroenteritis incidence B,C Acute gastroenteritis incidence B,D
Outpatient Inpatient Outpatient
0.66 (18) 36.82 (1009) 30.72 (842)
0.40 (11) 21.86 (599) 19.63 (538)
0.22 (6) 10.73 (294) 9.49 (260)
0.64 (18) 21.88 (612) 20.99 (587)
0.36 (10) 20.06 (561) 20.74 (580)
0.25 (7) 17.84 (499) 16.41 (459)
0.42 (70) 21.51 (3574) 19.66 (3266)
rom 6 to 11 months, ‘‘12” from 12 to 17 months and ‘‘18” from 18 to
t due to A08.0 (ICD-10).
0-A09 (ICD-10).
Table 3
Incidence of inpatient and outpatient rotavirus– and acute gastroenteritis in children born in 2014 and 2015. Children were followed from 6 to 23 months of age and
differentiated according to their vaccination status.
Birth year Vaccination status Age in months A Person-years Rotavirus gastroenteritis incidence B,C Acute gastroenteritis incidence B,D
Inpatient Outpatient Inpatient Outpatient
2014 + 6 26399 0.15 (4) 0.00 (0) 5.42 (143) 18.26 (482)
12 26399 0.11 (3) 0.00 (0) 4.28 (113) 17.31 (457)
18 26399 0.08 (2) 0.08 (2) 3.03 (80) 12.92 (341)
– 6 2260.5 2.65 (6) 0.00 (0) 9.29 (27) 17.25 (39)
12 2260.5 2.65 (6) 0.00 (0) 8.41 (25) 11.50 (26)
18 2260.5 2.65 (6) 0.44 (1) 4.42 (16) 16.81 (39)
2015 + 6 25556.5 0.16 (4) 0.00 (0) 5.44 (143) 19.72 (504)
12 25556.5 0.00 (0) 0.12 (3) 4.19 (107) 18.51 (476)
18 25556.5 0.08 (2) 0.04 (1) 4.03 (105) 13.73 (352)
– 6 2043.5 0.49 (1) 0.00 (0) 9.30 (20) 16.64 (34)
12 2043.5 1.47 (3) 0.00 (0) 4.40 (12) 24.96 (51)
18 2043.5 2.94 (6) 0.00 (0) 7.34 (21) 18.60 (38)
All vaccinated children (+) 155866.5 0.10 (15) 0.04 (6) 4.43 (691) 16.76 (2612)
All unvaccinated children (-) 12912.0 2.17 (28) 0.08 (1) 9.37 (121) 17.58 (227)
All children (+ & -) 168778.5 0.25 (43) 0.04 (7) 4.81 (812) 16.82 (2839)
+ = Children who have received at least one vaccine dose.
– = Children who have not received any vaccine doses.
A = Cohorts were divided into three age-groups; ‘‘600 includes episodes from 6 to 11 months, ‘‘12” from 12 to 17 months and ‘‘18” from 18 to 23 months.
B = (Number of cases) in parentheses.
C = Incidence of episodes [per 1000 person-years] with at least one visit due to A08.0 (ICD-10).
D = Incidence of episodes [per 1000 person-years] with visits due to A00-A09 (ICD-10).
Table 4
Vaccine effect (VE) types for inpatient and outpatient rotavirus gastroenteritis (RVGE) and acute infectious gastroenteritis (AGE).
VE (%)*
Inpatient RVGE Outpatient RVGE Inpatient AGE Outpatient AGE
VE type Overall 96.1 (95.7–96.4) 90.2 (90.0–90.3) 77.6 (76.8–78.5) 14.4 (13.5–15.4)
Total 98.5 (98.4–98.6) 90.9 (90.7–91.0) 79.4 (78.5–80.3) 14.8 (13.8–15.8)
Direct 95.6 (95.4–95.7) 50.3 (50.1–50.5) 52.7 (51.8–53.6) 4.7 (3.7–5.7)
Indirect 66.5 (65.9–67.2) 81.6 (81.6–81.7) 56.4 (55.6–57.3) 10.6 (9.6–11.6)
For VE calculation formulas, see Table 1.
* = Numbers in parentheses represent 95% confidence intervals.
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groups. All three age groups per year had the same amount of pyrs
because children who died within their follow up period were
excluded from the data.
Incidences were used to calculate overall, total, direct and indi-
rect VE. The formulas used in calculations are derived from a paper
by Halloran et al. (1997) [3] (Table 1.). Briefly, overall VE was cal-
culated by dividing the incidence in the post-vaccination era by
incidence in the pre-vaccination era. This entity is normally
reported in impact studies. Total VE was calculated by comparison
of incidences between vaccinated individuals in the post-vaccina-
tion era and all individuals in the pre-vaccination era. Direct VE
was calculated by comparing incidences among the vaccinated
and unvaccinated in the post-vaccination era, corresponding to
usually reported effectiveness. Indirect VE was calculated by com-
paring incidences among unvaccinated individuals in the post-vac-
cination era to incidences in the pre-vaccination era (Table 1.).2. Results
2.1. Overall reductions in acute gastroenteritis
2.1.1. Inpatient RVGE and AGE
During the pre-vaccination era (i.e. 2002–2005) 1076 episodes
of RVGE were registered in Finnish hospitals for children aged
0.5–2 years. This comes down to an incidence of 6.48 per 1000 pyrs(Table 2.). In the post-vaccination era (i.e. 2014–2017) there were a
total of 43 episodes of RVGE in children aged 0.5–2 years. Incidence
in the whole post-vaccination group for RVGE was 0.25 per 1000
pyrs (Table 3.). Overall VE regarding inpatient RVGE was therefore
96.1% (95% confidence interval being 95.7%–96.4%) (Table 4.). In
other words, after the implementation of the rotavirus vaccination
programme, the number of RVGE episodes has been reduced by an
estimated 96.1%. This corresponds to over 25-fold reduction in
incidence and an estimated 1051 (1049.8–1051.8) prevented epi-
sodes among the two birth cohorts followed from 6 to 23 months
of age.
In the pre-vaccination era, there were 3574 recorded episodes
of inpatient AGE with an incidence of 21.51 per 1000 pyrs (Table 2.)
For the post-vaccination era, the incidence of inpatient AGE was
4.81 with 812 episodes in total (Table 3.). Hence there were 4.5
times less episodes in the post-vaccination era than there were
in the pre-vaccination era. Overall VE for inpatient AGE was
77.6% (76.8%–78.5%) (Table 4.). Among the two birth cohorts fol-
lowed from 6 to 23 months of age, this corresponds to an estimated
2818 (2817.5–2819.6) prevented episodes.2.1.2. Secondary care outpatient RVGE and AGE
Outpatient RVGE among the children less than 2 years of age
has been rare in Finland with only 70 episodes and an incidence
of 0.42 per 1000 pyrs in the pre-vaccination era follow-up period
and 7 episodes and an incidence of 0.04 per 1000 pyrs in the
Fig. 1. Incidence of acute gastroenteritis in pre- and post-vaccination era among
children aged 0,5–2 years. RVGE = Rotavirus gastroenteritis; episodes with primary
diagnosis A08.0 (ICD-10). AGE = Acute infectious gastroenteritis; episodes with
primary diagnosis A00-A09 (ICD-10).
Fig. 2. Incidence of acute gastroenteritis between vaccinated and unvaccinated
children aged 0,5–2 years. RVGE = Rotavirus gastroenteritis; episodes with primary
diagnosis A08.0 (ICD-10). AGE = Acute infectious gastroenteritis; episodes with
primary diagnosis A00-A09 (ICD-10).
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tient RVGE is relatively rare, it’s noteworthy that there was a 10-
fold decrease in its incidence with overall VE being 90.2% (90.0%–
90.3%) (Table 4.).
Because RVGE rarely manifests as outpatient visits in health-
care, major reductions in incidences of outpatient AGE were not
expected. In the pre-vaccination era follow-up period, outpatient
AGE had an estimated incidence of 19.66 per 1000 pyrs (Table 2.).
In the post-vaccination era, the incidence was 16.82 per 1000 pyrs
(Table 3.). Although there was a reduction in incidence, it was rel-
atively small (Fig. 1.). This can also be seen in the overall and total
VE which were 14.4% (13.5%–15.4%) and 14.8% (13.8%–15.8%),
respectively (Table 4.). Hence, as expected, the rotavirus vaccina-
tion programme has not been profoundly reducing the burden of
secondary care outpatient AGE in Finland (Fig. 1. and Fig 2.).
Different effects of the vaccination programme between vacci-
nated and unvaccinated children
2.2. Inpatient RVGE
After the implementation of the national rotavirus vaccination
programme, inpatient RVGE episodes have practically vanished
among the vaccinated with only 15 episodes occurring in the
two birth cohorts followed from 6 to 24 months of age during years
2014–2017 (Table 3.). However, rotavirus continues to cause dis-
ease to the unvaccinated that had over 20 times higher risk for
having inpatient RVGE compared to vaccinated children (Fig. 3.)
as incidences were 0.10 and 2.17 per 1000 pyrs for vaccinated
and unvaccinated children, respectively (Table 3.). Direct VE wasconsequently estimated to be 95.6% (95.4%–95.7%) for inpatient
RVGE (Table 4.). Total VE (i.e. the maximum effect of vaccination
programme) was 98.5% (98.4%–98.6%). Indirect VE is a measure
of indirect protection gained by unvaccinated individuals in a pop-
ulation where vaccine coverage is high. In children born in 2014
and 2015, the indirect VE was 66.5% (65.9%–67.2%) for inpatient
RVGE (Table 4.). That is, during the post-vaccination era follow-
up period, there were 66.5% less episodes among the unvaccinated
than during the pre-vaccination era as a result of herd effect. Con-
verted into episodes, herd effect was responsible for preventing an
estimated 56 (55.1–57.3) inpatient RVGE episodes among the
unvaccinated during the follow-up from 6 to 23 months. It is note-
worthy that less than 10% of children in Finland are left unvacci-
nated against rotavirus and thus solely depend on the indirect
protection.2.3. Inpatient AGE
Since the rotavirus vaccine was added to the national vacci-
nation programme, there has been a major drop in the incidence
of inpatient AGE (Fig. 1.). When comparing pre-vaccination inci-
dences to vaccinated children in the post-vaccination era, the
reduction in incidence was approximately 4.9-fold (Fig. 2.) and
total VE was 79.4% (78.5%–80.3%)(Table 4.). In the unvaccinated
the effect was smaller; there was approximately a 2.3-fold
reduction in incidence (Fig. 2.). Indirect VE corresponding to
the herd effect for inpatient AGE was 56.4% (55.6%–57.3%) and
direct VE was 52.7% (51.8%–53.6%) (Table 4.). Herd effect was
responsible for preventing an estimated 157 (156.1–158.4) epi-
sodes of inpatient AGE among the unvaccinated during the fol-
low-up period.
Age-specific changes in incidence of acute gastroenteritis
In the pre-vaccination era, 6–11-month-old children had the
most episodes in every category analysed in this study (Figs. 3
and 4.). Among the unvaccinated children during the post-vaccina-
tion era, disease burden had shifted to older children as there were
more episodes of RVGE at the age of 18–23months (Fig. 3, Table 5.).
In addition, during the vaccination era, the AGE incidence did not
decrease as steeply with increasing age as it had done prior to
the vaccination programme (Fig. 4.). Incidences of inpatient RVGE
and AGE have become more balanced between the three age
groups (Table 5.) during the post-vaccination era. Furthermore, in
both vaccinated and unvaccinated children approaching 2 years,
incidences for outpatient AGE were slightly higher than in the
pre-vaccination era (Table 5, Fig. 4.), even though there was a
decrease in outpatient AGE episodes overall.3. Discussion
The national rotavirus vaccination programme has managed to
reduce not only specific RVGE but also additional inpatient AGE
cases not diagnosed as rotavirus disease. A typical case of RVGE
leads to hospitalization of the child. In our study, we report that
cases of inpatient RVGE have been reduced by 96% from 2002 to
2005 to 2014–2017 among children aged 6–23 months. The
national vaccination programme has had a widespread impact
beyond visits coded as RVGE, as cases of inpatient AGE have also
been reduced by approximately 78%. Converted into number of
cases, an estimated 2818 cases of inpatient gastroenteritis were
prevented. Of this, 1051 were coded specifically as RVGE.
A recent meta-analysis reports that rotavirus vaccinations by
RV5 (i.e. Rotateq) have reduced hospitalisations of RVGE by 94%
in countries of low child mortality [5]. Another systematic review
described a decrease of 94% in RVGE and 78% in AGE related hospi-
talisations in developed countries [6]. In a case-control study
Fig. 3. RVGE incidence by age-group in pre- and post-vaccination periods, vaccinated and unvaccinated children separated. RVGE = Rotavirus gastroenteritis; episodes with
primary diagnosis A08.0 (ICD-10).
Fig. 4. AGE incidence by age-group in pre- and post-vaccination periods, vaccinated and unvaccinated children separated. AGE = acute infectious gastroenteritis; episodes
with primary diagnosis A00-A09 (ICD-10).
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96% for inpatient and 83% for outpatient visits [7]. These results
are very much within the same range with our observed 96%
reduction in cases of inpatient RVGE. In addition, the reductions
seen in inpatient AGE by Lamberti et al., (2016) were same as ours
[6].
In previous studies conducted on Finnish children, observed
reductions in inpatient AGE and RVGE have been corresponding
to ours. A study based on a comparison of years 2012–2014 to
2006–2008 in Tampere University Hospital reported a 90% reduc-
tion in both inpatient and outpatient RVGE visits and a 59% reduc-
tion in all AGE cases [8]. In another Finnish study comparing years
2010–2014 to 1999–2005, the reductions seen in 0–1-year-old
children were 92–94% for inpatient RVGE [2]. In addition, a 74%
reduction in inpatient AGE was observed among 1-year old chil-
dren [2]. These results are in line with ours. Understandably, the
impact seen by us is slightly larger, for at the time of our study
the vaccination programme had been running for longer. Over 50
000 children are being vaccinated against rotavirus every year in
Finland, and as the years pass, the total amount of the vaccinated
rises and transmission of rotavirus decreases. Our study doesn’tstrive to represent the average impact of the whole vaccination
programme but rather to estimate its impact on children born after
2013.
Determining the baseline incidence is crucial for assessing the
impact of any vaccination programme. In this study children born
in 2002 and 2003 were chosen to represent the pre-vaccination
era. 2003 was a year of relatively high incidences of both inpatient
RVGE and AGE, but on the other hand year 2004 was the lowest
year of RVGE through 1999–2006 [9]. In our results, this can be
observed as children born in 2002 generally having higher inci-
dences of gastroenteritis than children born in 2003. Even though
these birth cohorts included notable seasonal variation, we
assessed that when summed, these years represent a realistic aver-
age of the pre-vaccination era of the early 2000 s. We believe that
choosing these years did not steer our results significantly in one
way or the other. In the post-vaccination group, there was no nota-
ble seasonal variation in gastroenteritis between children born in
2014 and 2015.
Rotavirus is rarely marked as the primary cause of gastroenteri-
tis for children as it is not routinely tested. This stems from the fact
that generally, a more precise diagnosis would not change the
Table 5
Incidences of acute gastroenteritis before and after implementation of rotavirus vaccination programme in Finland.
Time-period A Vaccination status Age in months B Person-years Rotavirus gastroenteritis
incidence C
Acute gastroenteritis
incidence D
Inpatient Outpatient Inpatient Outpatient
Pre-vaccination – 6 55376 9.03 0.65 29.27 25.81
12 55376 5.92 0.38 20.95 20.19
18 55376 4.48 0.23 14.32 12.98
All children 166128 6.48 0.42 21.51 19.66
Post-vaccination + 6 51955.5 0.15 0.00 5.50 18.98
12 51955.5 0.06 0.06 4.23 17.96
18 51955.5 0.08 0.06 3.56 13.34
All vaccinated children 155866.5 0.10 0.04 4.43 16.76
– 6 4304 1.63 0.00 10.92 16.96
12 4304 2.09 0.00 8.60 17.89
18 4304 2.79 0.23 8.60 17.89
All unvaccinated children 12912 2.17 0.08 9.37 17.58
+&– 6 56259.5 0.27 0.00 5.92 18.82
12 56259.5 0.21 0.05 4.57 17.95
18 56259.5 0.28 0.07 3.95 13.69
All children 168778.5 0.25 0.04 4.81 16.82
+ = Children who have received at least one vaccine dose
– = Children who have not received any vaccine doses. Vaccine was not available in pre-vaccination period.
A = Pre-vaccination time-period consists of children born in 2002 and 2003 and post-vaccination of children born in 2014 and 2015.
B = Cohorts were divided into three age-groups; ‘‘600 includes episodes from 6 to 11 months, ‘‘12” from 12 to 17 months and ‘‘18” from 18 to 23 months.
C = Incidence of episodes (per 1000 person-years) with at least one visit due to A08.0
D = Incidence of episodes (per 1000 person-years) with visits due to A00-A09
A. Solastie et al. / Vaccine 38 (2020) 3766–3772 3771course of treatment. In Finland too, RVGE is often undetected and
health care visits are coded with a more ambiguous code. Hence,
analysing only cases of rotavirus gastroenteritis would not repre-
sent the real impact of the national vaccination programme. In pur-
suit of more robust estimation, the AGE-category was incorporated
to the analysis. Containing diagnostic codes with similar symptoms
to RVGE, it catches the majority of undiagnosed RVGE cases but
contains also cases of other intestinal infectious diseases. In addi-
tion, by analysing incidences between the vaccinated and unvacci-
nated in the post-vaccination era, the effectiveness of the
vaccination programme could be evaluated in the real-world
setting.
When measuring total, direct and indirect VE outside vaccine
licensure studies, estimations are commonly made without infor-
mation on individual children’s vaccination status. Generally, herd
effect for RVGE have been described either on older children born
before programme implementation [10,11] or as estimations based
on vaccination coverage [12]. Here, we presented a more precise
estimation of herd effect by calculating indirect VE using individual
vaccination data. Of the 2818 prevented cases of inpatient AGE,
herd effect was responsible for preventing 157 cases. Of this, the
number of prevented inpatient RVGE cases was estimated to be
56. The high percentage of vaccinated children (92.9% of children
born in 2014–2015) has prevented an estimated 66.5% of inpatient
RVGE and 56.4% of inpatient AGE cases among the unvaccinated. In
a US study based on individual vaccination records, indirect VE
against RVGE on privately insured children rose from 14% at
2007 to 82% in 2010 with very limited rotavirus circulation [13].
For AGE indirect VE rose from –8 at 2007 to 45% in 2010.
As rotavirus rarely caused outpatient gastroenteritis among the
very young in Finland [2], the effect of the vaccination programme
was not expected to reduce the number of outpatient AGE cases in
this study. Recently, Leino et al. (2017) reported an increase in the
number of outpatient AGE cases among children under 5 during
2010–2014 [2]. Although we saw a slight reduction in the overall
incidence of outpatient AGE, there was an increase in cases occur-
ring among children aged 18–23 months. While results from the
2017 study by Leino et al. are not directly comparable to ours, asimilar trend can be seen. That is, the burden of acute gastroenteri-
tis among children in Finland is shifting from inpatient burden
towards children experiencing more cases of outpatient AGE.
A widely reported consequence of implementing a new vaccina-
tion programme is that while the rate of transmission decreases,
people fall ill later in life. This has also been associated with rota-
virus vaccinations globally [11,14], including in Finland [8,16].
Although our study focused solely on the very young, a shift of inci-
dence amongst the age groups studied could be observed. In the
pre-vaccination era, 6–11-month-old children had the most cases
of gastroenteritis in all categories analysed in this study. In the
post-vaccination era, unvaccinated children aged 12–17 and 18–
23 months had higher incidences of inpatient RVGE than children
aged 6–11 months. The explanation could well be that due to the
high vaccination coverage, virus circulation is somewhat limited
and virus is therefore merely acquired later. For a vaccine contain-
ing live virus, waning of the immunity during the first 1.5 years
post-vaccination is not very likely.
Although the vaccination programme demonstrates a strong
impact on reducing disease burden measured as hospital inpatient
and outpatient episodes among the very young, it has not been
able to prevent rotavirus from circulating in the population. Rota-
virus has kept its seasonality in Finland [8,15,17,18]. Furthermore,
it seems that new genotypes have arisen to replace the genotypes
that were dominant in the pre-vaccination era [8,16,17,18]. Similar
observations have been described in multiple countries [19,20].
Together with changes observed in the distribution of rotavirus
genotypes [8,16,17,18], our results indicate that continuous moni-
toring of rotavirus is still necessary.
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